Insuman Comb 25 (Insulin Human)

Insulin Human mimics the action of natural pancreatic insulin. It binds to insulin receptors on muscle, fat, and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen storage, and suppress hepatic glucose production, thereby lowering circulating blood sugar.

The dose of Insuman Comb 25 is individualized. A qualified prescriber determines the appropriate amount based on the patient’s blood‑glucose readings, diet, activity level, and overall treatment goals. Patients should follow the prescribing clinician’s instructions and adjust only under medical supervision.

Insulin is generally considered the preferred glucose‑lowering therapy during pregnancy because it does not cross the placenta. However, the safety of Insuman Comb 25 specifically has not been fully established, so it should be used only when clearly needed and under close medical supervision.

To request Insuman Comb 25, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Insuman Comb 25 contains human insulin, whereas many newer products use insulin analogues with altered absorption profiles. Human insulin provides reliable glucose‑lowering effects but may have a shorter onset and duration compared with rapid‑acting or long‑acting analogues, influencing dosing frequency and flexibility.

Insuman Comb 25 should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at room temperature (up to 30 °C) for a limited period, typically 28 days, as indicated on the label.

Insuman Comb 25 is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce lipodystrophy. Patients should be trained on proper technique, needle selection, and disposal of sharps according to local regulations.

The most serious risks include severe hypoglycaemia, which can lead to seizures or loss of consciousness, and rare allergic reactions such as anaphylaxis. Prompt recognition of symptoms and immediate medical attention are essential to mitigate these potentially life‑threatening events.

Insuman Comb 25 is contraindicated in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. Patients with recurrent severe hypoglycaemia despite dose adjustments, or those who cannot reliably monitor blood glucose, should discuss alternative therapies with their clinician.